Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Cipaglucosidase alfa	TA912 - Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
Cladribine injection	TA493 - Cladribine tablets for treating relapsing–remitting multiple sclerosis TA616 - Cladribine for treating relapsing–remitting multiple sclerosis	For hospital use only
Clobetasol propionate 0.05% cream	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Very potent
Clobetasol propionate 0.05% ointment	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Very potent
Clobetasol propionate 0.05% scalp application	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Very potent
Clobetasone butyrate 0.05% cream	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Moderate potency
Clobetasone butyrate 0.05% ointment	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Moderate potency
Clopidogrel 75mg tablets	TA80 - Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome TA210 - Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Colistimethate sodium	TA276 - Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis	Amber: Existing patients (initiated prior to April 2013) Promixin® - Powder for nebuliser solution Colomycin® Injection may be used for nebulisation; administer required dose in 2-4 mL of sodium chloride 0.9%, (or water for injections) or a 1:1 mixture of sodium chloride 0.9% and water for injection Colobreathe® - Dry powder for inhalation, hard capsule (NICE TA276)
Colistimethate sodium	TA276 - Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis	NHS England commissioned for cystic fibrosis only. Red for new patients.

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.